0 559

Cited 6 times in

Lack of anti-tumor activity by anti-VEGF treatments in hepatic hemangiomas

 Minsu Lee  ;  Jin-Young Choi  ;  Joon Seok Lim  ;  Mi-Suk Park  ;  Myeong-Jin Kim  ;  Honsoul Kim 
 ANGIOGENESIS, Vol.19(2) : 147-153, 2016 
Journal Title
Issue Date
Adult ; Aged ; Angiogenesis Inhibitors/therapeutic use* ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use* ; Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Female ; Hemangioma/diagnostic imaging ; Hemangioma/drug therapy* ; Humans ; Indoles/pharmacology ; Indoles/therapeutic use ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/secondary ; Male ; Middle Aged ; Pyrroles/pharmacology ; Pyrroles/therapeutic use ; Tomography, X-Ray Computed
Anti-VEGF treatment ; Bevacizumab ; Hepatic hemangioma ; Sunitinib
Recently, anti-vascular endothelial growth factor (anti-VEGF) agents have been described in the literature as a valid treatment option for symptomatic liver hemangiomas, but only limited evidence supports this notion. The purpose of this study was to elucidate whether or not the administration of anti-VEGF agents can reliably achieve a size reduction in liver hemangiomas. We examined patients with incidental hemangiomas who received anti-angiogenic agents for the treatment of other malignancies. Our study population consisted of 17 colorectal cancer patients and one lung cancer patient carrying 21 hemangiomas who received bevacizumab, and seven renal cell carcinoma patients carrying nine hepatic hemangiomas who received sunitinib. We have measured the liver hemangioma volume on both the pre-treatment and post-treatment computed tomography images and then calculated the volume alteration rates. No statistically significant difference (P = 0.365) in the volume of the liver hemangiomas was observed before (1.1-168.8 cm(3); mean ± SD 19.8 ± 39.7 cm(3)) or after (1.2-163.6 cm(3); 19.3 ± 38.0 cm(3)) bevacizumab treatment. The volume reduction rate ranged from -35.0 to 11.2 % (mean ± SD -1.3 ± 10.8 %). The sunitinib treatment group also showed no statistically significant difference (P = 0.889) in hemangioma volume before (1.2-6.5 cm(3); 3.0 ± 1.8 cm(3)) or after (1.2-6.0 cm(3); 3.0-1.7 cm(3)) treatment. The volume reduction rate ranged from -13.3 to 7.7 % (median: mean ± SD -2.5 ± 6.6 %). We did not observe liver hemangioma shrinkage after bevacizumab or sunitinib treatment. Our data do not support the application of anti-VEGF agents for the treatment of hepatic hemangiomas.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Myeong Jin(김명진) ORCID logo https://orcid.org/0000-0001-7949-5402
Kim, Hon Soul(김한솔)
Park, Mi-Suk(박미숙) ORCID logo https://orcid.org/0000-0001-5817-2444
Lee, Minsu(이민수)
Lim, Joon Seok(임준석) ORCID logo https://orcid.org/0000-0002-0334-5042
Choi, Jin Young(최진영) ORCID logo https://orcid.org/0000-0002-9025-6274
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.